Flashcards in Tumors of GI system Deck (42)
Loading flashcards...
1
Drugs used for anal cancer
cisplatin, mitomycin, 5FU
2
Drugs used for CRC
bevacizumab, capecitabine, cetuximab, 5FU
3
Drugs used for esophageal cancer
Cisplatin, Docetaxel, 5FU
4
Drugs used for gastric cancer
cisplatin, docetaxel, 5FU, trastuzumab
5
Drugs used for GI carcinoid
octreotide, interferon
6
Drugs used for GIST
imatinib, sunitinib
7
Drugs used for pancreatic cancer
5FU, erlotinib, gemcitabine
8
Drugs used for liver cancer
5FU
9
What is 1st/2nd line therapy for esophageal cancer?
Cisplatin + 5FU. docetaxel is 2nd line
10
How should you determine gastic cancer therapy
Check Her2 status. If positive, trastuzumab should be added to 5FU/cisplatin therapy
11
How do you determine CRC therapy?
Capecitbine or 5FU + bevacizumab or cetuximab unless KRAS +
12
What drug is associated with tachyphylaxis?
octreotide- duration of treatment is 12 months usually
13
Treatment with conventional chemo is GIST is futile due to ____.
overexpression of P-gp
14
GIST can be categorized into what groups?
KIT-mutant (80%), KIT negative, PDGFRA-mutant, wild-type
15
MOA bevacizumab
rhuMAab-VEGF
16
Bevacizumab issues
bleeding, perforation, wound dehisence, HTN
17
Capecitabine MOA
5FU prodrug
18
Capecitabine issues
DPD deficiency prevents metabolic activation. CI in renal dysfunction. Adverse CV events. Neuro and heme toxicities
19
Cetuximab MOA
EGFR Ab
20
Cetuximab issues
Cardiac arrest, respiratory arrest, sudden death, acneiform, infusion rxn
21
Cisplatin MOA
DNA crosslinks and adducts
22
Cisplatin issues
ototoxicity, NEPHROTOXICITY, BMS
23
Docetaxel MOA
Stabilize microtubule
24
Docetaxel issues
Increased tx related morality in NSCLC; edema, neuropathy, CI in hepatic disease, DLT: neutropenia
25
Erlotinib MOA
EGFR-TKI
26
Erlotinib issues
GI tox, bleeding, LFTs, ocular toxicities, rarely ILD
27
5FU MOA
pyrimidine antimetabolite that inhibits TS and interferes with RNA synthesis and effects DNA
28
5Fu issues
DPD deficiency = enhanced neurotoxicity, severe heme tox and BMS
29
Gemcitabine MOA
DNA polymerase inhibitor, incorporates triphosphate
30
Gemcitabine issues
BMS, infection, sensory peripheral neuropathy, arthralagia, drowsiness, anorexia resolves in 2-3 days
31
imatinib MOA
TKI adjuvant with resection of KIT mutant GIST
32
Imatinib issues
GI tox, CHF, neuro tox, fluid retention, edema
33
Inf-a MOA
enzyme activation following cell surface receptor binding and TK activation
34
inf-a issues
neuropsychiatric events, FLS
35
Mitomycin MOA
alkylating agent
36
Mitomycin issues
BMS, thrombocytopenia, leukopenia, HUS
37
Octreotide MOA
SS, reduce duodenal bicarb, amylase, gastric acidity, gallbladder contractility, bile secretion, inhibits meal induced increases in SMA and portal venous blood flow
38
Octreotide issues
monitor blood glucose, dose-related diarrhea
39
Sunitinib MOA
inhibitor of >80 RTKs
40
Sunitinib issues
Thrombocytopenia, bleeding, QT prolongation, GI complications including perforation
41
Trastuzumab MOA
HER2-neu antibody. Inhibition of Her2--> accumulation of cdk inhibitor p26--> cell cycle arrest. Inhibits constitutive Her2 shedding by MP (correlate with clinical activity)
42
